secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057501
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.03, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health completes enrollment in pivotal Phase 3 OnTarget trial; raises $1.86M in PIPE financing
--------------------------------------------------------------------------------

- Enrolled target 256 patients in Phase 3 OnTarget trial for crofelemer to prevent cancer therapy-related diarrhea; top-line results expected early Q4 2023.
- Private placement raises ~$1.86M via 137 Series G convertible preferred shares (convertible at $0.5423) and 6,850,000 warrants at $0.48 exercise price.
- Warrants exercisable from later of Jan 1, 2024 or stockholder approval, for 5 years; no anti-dilution or variable pricing.
- Standstill agreement with Iliad, Uptown, Streeterville suspends royalty payments for up to 6 months; they receive warrants for ~3.82M shares.
- Company agrees not to issue additional equity securities before Oct 22, 2023, except with PIPE investor consent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/0001104659-23-057501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923057501/tm2315061d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer